Potential of magnetic nanoparticles for targeted drug delivery

Nanotechnology, Science and Applications

Volumn 5, Issue 1, 2012, Pages 73-86

  Yang, Hung Wei ^a   Hua, Mu Yi ^a   Liu, Hao Li ^a   Huang, Chiung Yin ^a   Wei, Kuo Chen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Biomedical applications; Cancer therapy; Drug delivery; Magnetic nanoparticles

Indexed keywords

CARMUSTINE; DOXORUBICIN; EPIRUBICIN; MAGNETIC NANOPARTICLE; NANOCARRIER; PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; FEASIBILITY STUDY; HUMAN; HYPERTHERMIC THERAPY; IC 50; IMMUNOMAGNETIC SEPARATION; LOW DRUG DOSE; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; REVIEW; SURFACE PROPERTY; THERMOSTABILITY;

EID: 84866047965     PISSN: None     EISSN: 11778903     Source Type: Journal    
DOI: 10.2147/NSA.S35506     Document Type: Review

References (94)

1. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
2. Poizot P, Laruelle S, Grugeon S, Dupont L, Tarascon JM. Nano-sized transition-metal oxides as negative-electrode materials for lithium-ion batteries. Nature. 2000;407(6803):496-499.
3. Tari A, Chantrell RW, Charles SW, Popplewell J. The magnetic properties and stability of a ferrofluid containing Fe3O4 particles. Physica B and C. 1979;97(1):57-64.
4. Mahmoudi M, Simchi A, Imani M, Stroeve P, Sohrabi A. Templated growth of superparamagnetic iron oxide nanoparticles by temperature programming in the presence of poly(vinyl alcohol). Thin Solid Films. 2010;518(15):4281-4289.
5. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005;293(7):855-862.
6. Perez JM, Simeone FJ, Saeki Y, Josephson L, Weissleder R. Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media. J Am Chem Soc. 2003;125(34): 10192-10193.
7. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18(4):410-414.
8. Hong J, Xu J, Gong P, Yu J, Ma H, Yao S. Covalent-bonded immobilization of enzyme on hydrophilic polymer covering magnetic nanogels. Microporous Mesoporous Mater. 2008;109(1-3):470-477.
9. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577): 2404-2407.
10. Hua MY, Yang HW, Liu HL, et al. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials. 2011;32(34):8999-9010.
11. Hafeli UO, Sweeney SM, Beresford BA, Humm JL, Macklis RM. Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results. Nucl Med Biol. 1995;22(2):147-155.
12. Ying XY, Du YZ, Hong LH, Yuan H, Hu FQ. Magnetic lipid nanoparticles loading doxorubicin for intracellular delivery: preparation and characteristics. J Magn Magn Mater. 2011;323(8):1088-1093.
13. Nitin N, LaConte LE, Zurkiya O, Hu X, Bao G. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem. 2004;9(6):706-712.
14. Bogdanov AA Jr, Martin C, Weissleder R, Brady TJ. Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes. Biochim Biophys Acta. 1994; 1193(1):212-218.
15. Bulte JW, De Cuyper M. Magnetoliposomes as contrast agents. Methods Enzymol. 2003;373:175-198.
16. Bulte JW, Douglas T, Mann S, et al. Magnetoferritin: characterization of a novel superparamagnetic MR contrast agent. J Magn Reson Imaging. 1994;4(3):497-505.
17. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24(6):1001-1011.
18. Jiang W, Sun Z, Li F, et al. A novel approach to preparing magnetic protein microspheres with core-shell structure. J Magn Magn Mater. 2011;323(5):435-439.
19. Lin JJ, Chen JS, Huang SJ, et al. Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials. 2009;30(28):5114-5124.
20. Veiseh O, Kievit FM, Fang C, et al. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials. 2010;31(31):8032-8042.
21. Chen PY, Liu HL, Hua MY, et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro Oncol. 2010;12(10):1050-1060.
22. Cole AJ, David AE, Wang J, Galban CJ, Hill HL, Yang VC. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials. 2011;32(8):2183-2193.
23. Bi F, Zhang J, Su Y, Tang YC, Liu JN. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials. 2009;30(28):5125-5130.
24. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis. 2005;178(1):67-73.
25. Bradbury M, Hricak H. Molecular MR imaging in oncology. Magn Reson Imaging Clin N Am. 2005;13(2):225-240.
26. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia. 2006;8(3):214-222.
27. Shen T, Weissleder R, Papisov M, Bogdanov A Jr, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med. 1993;29(5):599-604.
28. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319-2331.
29. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38.
30. Lee H, Lee E, Kim do K, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc. 2006;128(22):7383-7389.
31. Lacava LM, Lacava ZG, Da Silva MF, et al. Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. Biophys J. 2001;80(5):2483-2486.
32. Davis SS. Biomedical applications of nanotechnology - implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15(6): 217-224.
33. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm. 2000;202(1-2):1-10.
34. Jeong YI, Seo SJ, Park IK, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(γ-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005;296(1-2):151-161.
35. Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, Mohapatra SS. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine. 2007;3(2):132-137.
36. Shi X, Thomas TP, Myc LA, Kotlyar A, Baker JR Jr. Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys. 2007;9(42):5712-5720.
37. Hua MY, Yang HW, Chuang CK, et al. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials. 2010; 31(28):7355-7363.
38. Hua MY, Liu HL, Yang HW, et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials. 2011;32(2):516-527.
39. Yang HW, Hua MY, Liu HL, et al. Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials. 2011;32(27):6523-6532.
40. Yang HW, Hua MY, Liu HL, et al. An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer. Biomaterials. 2012;33(15):3919-3930.
41. Yang HW, Hua MY, Liu HL, et al. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy. ACS Nano. 2012;6(2):1795-1805.
42. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2(8):495-499.
43. Dini L, Abbro L. Bioeffects of moderate-intensity static magnetic fields on cell cultures. Micron. 2005;36(3):195-217.
44. Arias JL, Gallardo V, Gomez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release. 2001;77(3):309-321.
45. Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials. 2006;27(33):5725-5733.
46. Ikeda N, Hayashida O, Kameda H, Ito H, Matsuda T. Experimental study on thermal damage to dog normal brain. Int J Hyperthermia. 1994;10(4):553-561.
47. Goldstein LS, Dewhirst MW, Repacholi M, Kheifets L. Summary, conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia. 2003;19(3):373-384.
48. Matsuoka F, Shinkai M, Honda H, Kubo T, Sugita T, Kobayashi T. Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagn Res Technol. 2004;2(1):3.
49. Du Y, Zhang D, Liu H, Lai R. Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9. BMC Biotechnol. 2009;9:84.
50. Jang JT, Nah H, Lee JH, Moon SH, Kim MG, Cheon J. Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew Chem Int Ed Engl. 2009;48(7): 1234-1238.
51. Saiyed ZM, Telang SD, Racnchand CN. Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn Res Technol. 2003;1(1):23-33.
52. Schneider S, Rusconi S. Magnetic selection of transiently transfected cells. Biotechniques. 1996;21(5):876-880.
53. Spanova A, Rittich B, Horak D, et al. Immunomagnetic separation and detection of Salmonella cells using newly designed carriers. J Chromatogr A. 2003;1009(1-2):215-221.
54. Bornscheuer UT. Immobilizing enzymes: how to create more suitable biocatalysts. Angew Chem Int Ed Engl. 2003;42(29): 3336-3337.
55. Liao MH, Chen DH. Immobilization of yeast alcohol dehydrogenase on magnetic nanoparticles for improving its stability. Biotechnol Lett. 2001;23(20):1723-1727.
56. Huang SH, Liao MH, Chen DH. Direct binding and characterization of lipase onto magnetic nanoparticles. Biotechnol Prog. 2003;19(3): 1095-1100.
57. Libertino S, Scandurra A, Aiello V, et al. Layer uniformity in glucose oxidase immobilization on SiO2 surfaces. Appl Surf Sci. 2007;253(23): 9116-9123.
58. Park HJ, McConnell JT, Boddohi S, Kipper MJ, Johnson PA. Synthesis and characterization of enzyme-magnetic nanoparticle complexes: effect of size on activity and recovery. Colloid Surf B Biointerfaces. 2011;83(2):198-203.
59. Dyal A, Loos K, Noto M, et al. Activity of Candida rugosa lipase immobilized on γ-Fe2O3 magnetic nanoparticles. J Am Chem Soc. 2003; 125(7):1684-1685.
60. Huang J, Zhao R, Wang H, Zhao W, Ding L. Immobilization of glucose oxidase on Fe3O4/SiO2 magnetic nanoparticles. Biotechnol Lett. 2010; 32(6):817-821.
61. Akutsu J, Tojo Y, Segawa O, et al. Development of an integrated automation system with a magnetic bead-mediated nucleic acid purification device for genetic analysis and gene manipulation. Biotechnol Bioeng. 2004;86(6):667-671.
62. Georgieva J, Milling A, Orfanos CE, Geilen CC. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Res. 2002;12(4):309-317.
63. Archer MJ, Lin B, Wang Z, Stenger DA. Magnetic bead-based solid phase for selective extraction of genomic DNA. Anal Biochem. 2006; 355(2):285-297.
64. Wang L, Yang Z, Gao J, et al. A biocompatible method of decorporation: bisphosphonate-modified magnetite nanoparticles to remove uranyl ions from blood. J Am Chem Soc. 2006;128(41):13358-13359.
65. Herrmann IK, Urner M, Koehler FM, et al. Blood purification using functionalized core/shell nanomagnets. Small. 2010;6(13):1388-1392.
66. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5): 545-580.
67. Guimaraes AR, Ross R, Figuereido JL, Waterman P, Weissleder R. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. Mol Imaging Biol. 2011;13(2): 314-320.
68. Korosoglou G, Tang L, Kedziorek D, et al. Positive contrast MR-lymphography using inversion recovery with ON-resonant water suppression (IRON). J Magn Reson Imaging. 2008;27(5):1175-1180.
69. Morishige K, Kacher DF, Libby P, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010;122(17): 1707-1715.
70. Sosnovik DE, Nahrendorf M, Panizzi P, et al. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging. 2009;2(6):468-475.
71. Shen CR, Wu ST, Tsai ZT, et al. Characterization of quaternized chitosan-stabilized iron oxide nanoparticles as a novel potential magnetic resonance imaging contrast agent for cell tracking. Polym Int. 2011; 60(6):945-950.
72. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002;9(2):102-109.
73. Krötz F, de Wit C, Sohn HY, et al. Magnetofection - a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther. 2003;7(5 Pt 1):700-710.
74. Hirao K, Sugita T, Kubo T, et al. Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol. 2003;22(5):1065-1071.
75. Zheng X, Lu J, Deng L, Xiongc Y, Chen J. Preparation and characterization of magnetic cationic liposome in gene delivery. Int J Pharm. 2009;366(1-2):211-217.
76. Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release. 2007;122(3):315-323.
77. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-496.
78. Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010;107(34): 15205-15210.
79. Liu HL, Hsu PH, Chu PC, et al. Magnetic resonance imaging enhanced by superparamagnetic iron oxide particles: usefulness for distinguishing between focused ultrasound-induced blood-brain barrier disruption and brain hemorrhage. J Magn Reson Imaging. 2009;29(1):31-38.
80. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002;90(2):162-173.
81. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int. 2002;90(2):174-184.
82. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
83. Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006; 6(4):669-676.
84. Min K, Jo H, Song K, et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials. 2011;32(8):2124-2132.
85. Sanna V, Pintus G, Roggio AM, et al. Targeted biocompatible nanoparticles for the delivery of (I)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem. 2011;54(5):1321-1332.
86. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21(21):2133-2148.
87. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24):6317-6324.
88. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011;14(3):150-163.
89. Dietel M. What's new in cytostatic drug resistance and pathology. Pathol Res Pract. 1991;187(7):892-905.
90. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells. 1990;2(1):15-22.
91. Hammond JR, Johnstone RM, Gros P. Enhanced efflux of (3H)vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. Cancer Res. 1989; 49(14):3867-3871.
92. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosilation potentiates cellular multidrug resistance. FASEB J. 2001;15(3):719-730.
93. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hemat. 2000;36(2-3):193-207.
94. Nam HY, Kwon SM, Chung H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009;135(3):259-267.